EG24533A - Piperdine derivatives useful as CCR 5 antagonists - Google Patents

Piperdine derivatives useful as CCR 5 antagonists

Info

Publication number: EG24533A
Authority: EG; Egypt
Prior art keywords: ccr; antagonists; derivatives useful; piperdine derivatives; piperdine
Prior art date: 1999-05-04

Application number

EG20000563A

Other languages

English (en)

Inventor

Bahige M Baroudy

John W Clader

Hubert B Josien

Stuart W Mccombie

Brian A Mckittrick

Michael W Miller

Bernard R Neustadt

Anandan Palani

Ruo Steensma

Jayaram R Tagat

Susan F Vice

Mark A Laughlin

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-04

Filing date

2000-05-02

Publication date

2009-08-30

2000-05-02 Application filed by Schering Corp filed Critical Schering Corp

2009-08-30 Application granted granted Critical

2009-08-30 Publication of EG24533A publication Critical patent/EG24533A/xx

Links

NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
239000005557 antagonist Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
AIDS & HIV (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EG20000563A 1999-05-04 2000-05-02 Piperdine derivatives useful as CCR 5 antagonists EG24533A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30518799A	1999-05-04	1999-05-04

Publications (1)

Publication Number	Publication Date
EG24533A true EG24533A (en)	2009-08-30

Family

ID=23179704

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EG20000563A EG24533A (en)	1999-05-04	2000-05-02	Piperdine derivatives useful as CCR 5 antagonists

Country Status (32)

Country	Link
EP (2)	EP1175402B1 (de)
JP (3)	JP3894729B2 (de)
KR (1)	KR100439357B1 (de)
CN (2)	CN1524527A (de)
AR (1)	AR023939A1 (de)
AT (1)	ATE299866T1 (de)
AU (2)	AU780983B2 (de)
BR (1)	BR0010607A (de)
CA (1)	CA2371587C (de)
CO (1)	CO5170522A1 (de)
CZ (1)	CZ301161B6 (de)
DE (1)	DE60021371T2 (de)
DK (1)	DK1175402T3 (de)
EG (1)	EG24533A (de)
ES (1)	ES2246233T3 (de)
HK (1)	HK1039330B (de)
HU (1)	HUP0203528A3 (de)
IL (1)	IL145742A0 (de)
MY (1)	MY141473A (de)
NO (1)	NO322044B1 (de)
NZ (1)	NZ514675A (de)
PE (1)	PE20010113A1 (de)
PL (1)	PL203117B1 (de)
PT (1)	PT1175402E (de)
RU (2)	RU2266281C2 (de)
SA (1)	SA00210270B1 (de)
SI (1)	SI1175402T1 (de)
SK (1)	SK286968B6 (de)
TR (2)	TR200402496T2 (de)
TW (1)	TWI283666B (de)
WO (1)	WO2000066559A1 (de)
ZA (1)	ZA200108867B (de)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR033517A1 (es)	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
US20050065319A1 (en) *	2000-12-19	2005-03-24	Baroudy Bahige M.	Combination method for treating viral infections
AR033452A1 (es)	2001-03-29	2003-12-17	Schering Corp	Antagonistas de ccr5 utiles para el tratamiento del sida
GB0108876D0 (en) *	2001-04-09	2001-05-30	Novartis Ag	Organic Compounds
ATE319703T1 (de) *	2001-07-02	2006-03-15		Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0120461D0 (en) *	2001-08-22	2001-10-17	Astrazeneca Ab	Novel compounds
AR036366A1 (es) *	2001-08-29	2004-09-01	Schering Corp	Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en)	2001-09-18	2001-11-07	Astrazeneca Ab	Chemical compounds
US6818773B2 (en) *	2001-10-15	2004-11-16	Schering Corporation	Synthesis of 4-[(Z)-4-bromophenyl)(ethoxyimino) methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbony)]-4'-methyl-1,4-′bipiperidine
AR036882A1 (es) *	2001-10-15	2004-10-13	Schering Corp	Sintesis de (4-bromofenil)(4-piperidil)metanona-(z)-o-etiloxima y sales
CA2467555A1 (en) *	2001-11-29	2003-08-14	Schering Corporation	Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl)-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-me thyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections
EP2311818B1 (de)	2002-02-28	2013-01-16	Novartis AG	Kombination aus einem 5-phenylthiazolderivat als PI3-Kinasehemmer und eine entzündungshemmender, bronchodilatatorische oder antihistaminischen Verbindung
SE0200843D0 (sv) *	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
SE0200844D0 (sv)	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
US6992189B2 (en)	2002-03-29	2006-01-31	Schering Corporation	Synthesis of piperidine and piperazine compounds as CCR5 antagonists
US20050245537A1 (en) *	2002-04-24	2005-11-03	Noboru Tsuchimori	Use of compounds having ccr antagonism
WO2004026833A1 (ja) *	2002-09-20	2004-04-01	Takeda Pharmaceutical Company Limited	環状アミン化合物、その製造法および用途
JP2004107298A (ja) *	2002-09-20	2004-04-08	Takeda Chem Ind Ltd	ウレア化合物およびその用途
GB0223223D0 (en) *	2002-10-07	2002-11-13	Novartis Ag	Organic compounds
US7645771B2 (en) *	2002-12-13	2010-01-12	Smithkline Beecham Corp.	CCR5 antagonists as therapeutic agents
PE20040769A1 (es) *	2002-12-18	2004-11-06	Schering Corp	Derivados de piperidina utiles como antagonisas ccr5
RU2366655C2 (ru)	2003-03-14	2009-09-10	Оно Фармасьютикал Ко., Лтд.	Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
SE0300957D0 (sv)	2003-04-01	2003-04-01	Astrazeneca Ab	Chemical compounds
WO2004092169A1 (ja)	2003-04-18	2004-10-28	Ono Pharmaceutical Co., Ltd.	スピロピペリジン化合物およびその医薬用途
US20070043079A1 (en) *	2003-04-18	2007-02-22	Hiromu Habashita	Heterocyclic compound containing nitrogen atom and use thereof
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
RU2006100190A (ru) *	2003-06-13	2006-08-10	Шеринг Акциенгезельшафт (De)	Производные хинолиламида в качестве антагонистов ccr-5
US7161024B2 (en)	2003-07-10	2007-01-09	Schering Corporation	Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters
SE0302956D0 (sv) *	2003-11-07	2003-11-07	Astrazeneca Ab	Chemical compounds
US7498346B2 (en) *	2003-12-11	2009-03-03	Genzyme Corporation	Chemokine receptor binding compounds
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
RU2006132465A (ru)	2004-02-10	2008-03-20	Ф.Хоффманн-Ля Рош Аг (Ch)	Модуляторы хемокинового рецептора ccr5
SE0400925D0 (sv) *	2004-04-06	2004-04-06	Astrazeneca Ab	Chemical compounds
EA015517B1 (ru)	2004-04-13	2011-08-30	Инсайт Корпорейшн	Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
ATE382623T1 (de)	2004-06-09	2008-01-15	Hoffmann La Roche	Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln
US8143404B2 (en) *	2004-09-13	2012-03-27	Ono Pharmaceutical Co., Ltd	Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
CA2595574A1 (en) *	2005-01-20	2006-07-27	Pfizer Limited.	Chemical compounds
JP4873352B2 (ja) *	2005-02-16	2012-02-08	シェーリングコーポレイション	Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換されたピペラジン
EP1858887A1 (de) *	2005-02-23	2007-11-28	Schering Corporation	Als inhibitoren von chemokinrezeptoren geeignete piperidinylpiperazinderivate
JP4822367B2 (ja) *	2005-02-23	2011-11-24	シェーリングコーポレイション	ケモカイン受容体のインヒビターとして有用なピペリジニルピペリジン誘導体
GB0507577D0 (en)	2005-04-14	2005-05-18	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
EP1889622A4 (de)	2005-05-31	2009-12-23	Ono Pharmaceutical Co	Spiropiperidinverbindung und deren medizinische verwendung
US7665658B2 (en)	2005-06-07	2010-02-23	First Data Corporation	Dynamic aggregation of payment transactions
JP2009501793A (ja)	2005-07-21	2009-01-22	アストラゼネカ・アクチエボラーグ	新規ピペリジン誘導体
CN101291905A (zh)	2005-10-19	2008-10-22	弗·哈夫曼-拉罗切有限公司	苯乙酰胺nnrt抑制剂
WO2007045477A2 (en)	2005-10-21	2007-04-26	Novartis Ag	Human antibodies against il-13 and therapeutic uses
EP2657235A1 (de)	2005-10-28	2013-10-30	Ono Pharmaceutical Co., Ltd.	Verbindung mit basischer Gruppe und Verwendung davon
WO2007058322A1 (ja)	2005-11-18	2007-05-24	Ono Pharmaceutical Co., Ltd.	塩基性基を含有する化合物およびその用途
GB0525671D0 (en)	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
GB0526244D0 (en)	2005-12-22	2006-02-01	Novartis Ag	Organic compounds
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
CA2644368A1 (en)	2006-03-10	2007-09-20	Ono Pharmaceutical Co., Ltd.	Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EP2059515A2 (de) *	2006-04-12	2009-05-20	Pfizer Limited	Pyrrolidinderivate als modulatoren von chemokin-ccr5-rezeptoren
PT2322525E (pt)	2006-04-21	2013-12-26	Novartis Ag	Derivados de purina para utilização como agonistas do recetor de adenosina a2a
WO2007132846A1 (ja)	2006-05-16	2007-11-22	Ono Pharmaceutical Co., Ltd.	保護されていてもよい酸性基を含有する化合物およびその用途
JP5245827B2 (ja)	2006-07-31	2013-07-24	小野薬品工業株式会社	スピロ結合した環状基を含有する化合物およびその用途
RU2451676C2 (ru)	2006-08-16	2012-05-27	Ф.Хоффманн-Ля Рош Аг	Ненуклеозидные ингибиторы обратной транскриптазы
WO2008037477A1 (en)	2006-09-29	2008-04-03	Novartis Ag	Pyrazolopyrimidines as p13k lipid kinase inhibitors
MX2009005881A (es)	2006-12-13	2009-06-12	Hoffmann La Roche	Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
RS51644B (sr)	2007-01-10	2011-10-31	Irm Llc.	Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
WO2008119663A1 (en)	2007-03-29	2008-10-09	F. Hoffmann-La Roche Ag	Heterocyclic antiviral compounds
CN101687851B (zh)	2007-05-07	2013-02-27	诺瓦提斯公司	有机化合物
CL2008003651A1 (es)	2007-12-10	2009-06-19	Novartis Ag	Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
CA2716838C (en) *	2008-02-29	2014-01-07	Schering Corporation	Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US8268834B2 (en)	2008-03-19	2012-09-18	Novartis Ag	Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
CA2727196A1 (en)	2008-06-10	2009-12-17	Novartis Ag	Organic compounds
PL2391366T3 (pl)	2009-01-29	2013-04-30	Novartis Ag	Podstawione benzimidazole do leczenia gwiaździaków
WO2010129351A1 (en)	2009-04-28	2010-11-11	Schepens Eye Research Institute	Method to identify and treat age-related macular degeneration
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru)	2009-08-12	2012-09-28	Новартис Аг	Гетероциклические гидразоны и их применение для лечения рака и воспаления
NZ598220A (en)	2009-08-17	2014-02-28	Intellikine Llc	Heterocyclic compounds and uses thereof
CA2771432A1 (en)	2009-08-20	2011-02-24	Novartis Ag	Heterocyclic oxime compounds
US20110098311A1 (en)	2009-10-22	2011-04-28	Vertex Pharmaceuticals Incorported	Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
PT2593452T (pt)	2010-07-14	2017-04-24	Novartis Ag	Compostos heterocíclicos agonistas do receptor ip
US8372845B2 (en)	2010-09-17	2013-02-12	Novartis Ag	Pyrazine derivatives as enac blockers
EP2673277A1 (de)	2011-02-10	2013-12-18	Novartis AG	[1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
WO2012116237A2 (en)	2011-02-23	2012-08-30	Intellikine, Llc	Heterocyclic compounds and uses thereof
WO2013024022A1 (en)	2011-08-12	2013-02-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US8883819B2 (en)	2011-09-01	2014-11-11	Irm Llc	Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CA2848809A1 (en)	2011-09-15	2013-03-21	Novartis Ag	6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
WO2013038373A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
WO2013038378A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
WO2013038386A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038381A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine/pyrazine amide derivatives
ES2882807T3 (es)	2011-09-16	2021-12-02	Novartis Ag	Heterociclil carboxamidas N-sustituidas
EP2780015B1 (de)	2011-11-18	2017-01-04	Heptares Therapeutics Limited	M1 muskarinrezeptoragonisten
JP6130391B2 (ja)	2011-11-23	2017-05-17	インテリカイン，エルエルシー	Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US9115129B2 (en)	2012-01-13	2015-08-25	Novartis Ag	Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
US20150005311A1 (en)	2012-01-13	2015-01-01	Novartis Ag	IP receptor agonist heterocyclic compounds
US20140357641A1 (en)	2012-01-13	2014-12-04	Novartis Ag	IP receptor agonist heterocyclic compounds
US9174985B2 (en)	2012-01-13	2015-11-03	Novartis Ag	Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists
UY34572A (es)	2012-01-13	2013-09-02	Novartis Ag	Compuestos heterocíclicos agonistas del receptor ip
WO2013105058A1 (en)	2012-01-13	2013-07-18	Novartis Ag	7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US8809340B2 (en)	2012-03-19	2014-08-19	Novartis Ag	Crystalline form
AU2013243097A1 (en)	2012-04-03	2014-10-09	Novartis Ag	Combination products with tyrosine kinase inhibitors and their use
JP6478923B2 (ja)	2013-02-07	2019-03-06	ヘプタレスセラピューティクスリミテッドＨｅｐｔａｒｅｓＴｈｅｒａｐｅｕｔｉｃｓＬｉｍｉｔｅｄ	ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
CN105189500A (zh)	2013-02-13	2015-12-23	诺华股份有限公司	Ip受体激动剂杂环化合物
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (de)	2013-03-15	2016-08-10	Intellikine Llc	Kombination von kinaseinhibitoren und verwendungen davon
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
KR20160098424A (ko)	2013-12-19	2016-08-18	바이엘 파마 악티엔게젤샤프트	치환된 피페리디닐-테트라히드로퀴놀린
US20160318866A1 (en)	2013-12-19	2016-11-03	Bayer Pharma Aktiengesellschaft	Substituted bipiperidinyl derivatives
CR20160276A (es)	2013-12-19	2016-10-20	Bayer Pharma AG	"piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c"
EP3083610A1 (de)	2013-12-19	2016-10-26	Bayer Pharma Aktiengesellschaft	Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
GB201404922D0 (en)	2014-03-19	2014-04-30	Heptares Therapeutics Ltd	Pharmaceutical compounds
CA2945212A1 (en)	2014-04-24	2015-10-29	Novartis Ag	Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US9862711B2 (en)	2014-04-24	2018-01-09	Novartis Ag	Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016024484A2 (pt)	2014-04-24	2017-08-15	Novartis Ag	derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
CA2954862A1 (en)	2014-07-31	2016-02-04	Novartis Ag	Combination therapy
GB201513743D0 (en)	2015-08-03	2015-09-16	Heptares Therapeutics Ltd	Muscarinic agonists
GB201519352D0 (en) *	2015-11-02	2015-12-16	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB201617454D0 (en)	2016-10-14	2016-11-30	Heptares Therapeutics Limited	Pharmaceutical compounds
GB201810239D0 (en)	2018-06-22	2018-08-08	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB201819960D0 (en)	2018-12-07	2019-01-23	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB201819961D0 (en)	2018-12-07	2019-01-23	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB202020191D0 (en)	2020-12-18	2021-02-03	Heptares Therapeutics Ltd	Pharmaceutical compounds
AU2020290094B2 (en)	2019-06-10	2024-01-18	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
AU2020338971B2 (en)	2019-08-28	2023-11-23	Novartis Ag	Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US11629196B2 (en)	2020-04-27	2023-04-18	Incelldx, Inc.	Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2676054B1 (fr) *	1991-05-03	1993-09-03	Sanofi Elf	Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5889006A (en) *	1995-02-23	1999-03-30	Schering Corporation	Muscarinic antagonists
ES2182104T3 (es) *	1996-07-10	2003-03-01	Schering Corp	Piperidinas 1,4-disustituidas como antagonistas muscarinicos.
AU6623796A (en) *	1996-07-25	1998-02-20	Terence George Mackay	Improvements in or relating to fishing
JP3390179B2 (ja) *	1996-08-15	2003-03-24	シェーリングコーポレイション	エーテルムスカリン様アンタゴニスト
CA2296314A1 (en) *	1997-07-25	1999-02-04	Merck & Co., Inc.	Cyclic amine modulators of chemokine receptor activity

2000
- 2000-05-01 KR KR10-2001-7013862A patent/KR100439357B1/ko not_active Expired - Fee Related
- 2000-05-01 HU HU0203528A patent/HUP0203528A3/hu unknown
- 2000-05-01 EP EP00926487A patent/EP1175402B1/de not_active Expired - Lifetime
- 2000-05-01 SI SI200030719T patent/SI1175402T1/xx unknown
- 2000-05-01 DE DE60021371T patent/DE60021371T2/de not_active Expired - Lifetime
- 2000-05-01 IL IL14574200A patent/IL145742A0/xx unknown
- 2000-05-01 CN CNA2004100282860A patent/CN1524527A/zh active Pending
- 2000-05-01 AT AT00926487T patent/ATE299866T1/de not_active IP Right Cessation
- 2000-05-01 WO PCT/US2000/011633 patent/WO2000066559A1/en not_active Ceased
- 2000-05-01 PT PT00926487T patent/PT1175402E/pt unknown
- 2000-05-01 CA CA002371587A patent/CA2371587C/en not_active Expired - Fee Related
- 2000-05-01 TR TR2004/02496T patent/TR200402496T2/xx unknown
- 2000-05-01 ES ES00926487T patent/ES2246233T3/es not_active Expired - Lifetime
- 2000-05-01 EP EP05010590A patent/EP1659111A3/de not_active Withdrawn
- 2000-05-01 NZ NZ514675A patent/NZ514675A/en not_active IP Right Cessation
- 2000-05-01 CZ CZ20013941A patent/CZ301161B6/cs not_active IP Right Cessation
- 2000-05-01 BR BR0010607-0A patent/BR0010607A/pt not_active Application Discontinuation
- 2000-05-01 AU AU45010/00A patent/AU780983B2/en not_active Ceased
- 2000-05-01 JP JP2000615390A patent/JP3894729B2/ja not_active Expired - Fee Related
- 2000-05-01 DK DK00926487T patent/DK1175402T3/da active
- 2000-05-01 SK SK1567-2001A patent/SK286968B6/sk not_active IP Right Cessation
- 2000-05-01 RU RU2001132635/04A patent/RU2266281C2/ru not_active IP Right Cessation
- 2000-05-01 PL PL351412A patent/PL203117B1/pl not_active IP Right Cessation
- 2000-05-01 TR TR2001/03213T patent/TR200103213T2/xx unknown
- 2000-05-01 HK HK02100825.9A patent/HK1039330B/en not_active IP Right Cessation
- 2000-05-01 CN CNB008071683A patent/CN1151131C/zh not_active Expired - Fee Related
- 2000-05-02 PE PE2000000406A patent/PE20010113A1/es not_active Application Discontinuation
- 2000-05-02 TW TW089108325A patent/TWI283666B/zh active
- 2000-05-02 AR ARP000102095A patent/AR023939A1/es unknown
- 2000-05-02 EG EG20000563A patent/EG24533A/xx active
- 2000-05-02 CO CO00031252A patent/CO5170522A1/es not_active Application Discontinuation
- 2000-05-02 MY MYPI20001891A patent/MY141473A/en unknown
- 2000-08-05 SA SA00210270A patent/SA00210270B1/ar unknown
2001
- 2001-10-26 ZA ZA200108867A patent/ZA200108867B/xx unknown
- 2001-11-02 NO NO20015365A patent/NO322044B1/no not_active IP Right Cessation
2005
- 2005-05-31 AU AU2005202358A patent/AU2005202358B2/en not_active Ceased
- 2005-06-23 RU RU2005120376/15A patent/RU2005120376A/ru not_active Application Discontinuation
2006
- 2006-05-31 JP JP2006152916A patent/JP2006225407A/ja not_active Withdrawn
2011
- 2011-07-07 JP JP2011151208A patent/JP2011219493A/ja active Pending

Also Published As

Publication number	Publication date
WO2000066559A1 (en)	2000-11-09
RU2005120376A (ru)	2006-12-27
BR0010607A (pt)	2002-02-13
KR20020019906A (ko)	2002-03-13
SK286968B6 (sk)	2009-08-06
ATE299866T1 (de)	2005-08-15
TWI283666B (en)	2007-07-11
DE60021371D1 (de)	2005-08-25
CN1349504A (zh)	2002-05-15
ZA200108867B (en)	2003-03-26
DK1175402T3 (da)	2005-11-21
HUP0203528A2 (hu)	2003-02-28
MY141473A (en)	2010-04-30
NZ514675A (en)	2004-05-28
CA2371587A1 (en)	2000-11-09
CA2371587C (en)	2005-09-13
IL145742A0 (en)	2002-07-25
JP2011219493A (ja)	2011-11-04
KR100439357B1 (ko)	2004-07-07
AR023939A1 (es)	2002-09-04
SA00210270B1 (ar)	2006-09-04
AU780983B2 (en)	2005-04-28
SI1175402T1 (en)	2005-10-31
AU2005202358A1 (en)	2005-06-23
NO20015365D0 (no)	2001-11-02
EP1659111A3 (de)	2007-05-09
SK15672001A3 (sk)	2002-06-04
CN1151131C (zh)	2004-05-26
CN1524527A (zh)	2004-09-01
AU4501000A (en)	2000-11-17
EP1175402B1 (de)	2005-07-20
HK1039330A1 (en)	2002-04-19
CO5170522A1 (es)	2002-06-27
EP1659111A2 (de)	2006-05-24
HUP0203528A3 (en)	2003-11-28
PE20010113A1 (es)	2001-02-05
PL203117B1 (pl)	2009-08-31
RU2266281C2 (ru)	2005-12-20
EP1175402A1 (de)	2002-01-30
TR200402496T2 (tr)	2005-01-24
JP3894729B2 (ja)	2007-03-22
JP2006225407A (ja)	2006-08-31
CZ20013941A3 (cs)	2002-04-17
ES2246233T3 (es)	2006-02-16
HK1039330B (en)	2005-12-09
DE60021371T2 (de)	2006-04-27
TR200103213T2 (tr)	2002-03-21
AU2005202358B2 (en)	2008-01-10
JP2002543186A (ja)	2002-12-17
CZ301161B6 (cs)	2009-11-18
PL351412A1 (en)	2003-04-22
NO20015365L (no)	2002-01-03
PT1175402E (pt)	2005-11-30
NO322044B1 (no)	2006-08-07

Publication	Publication Date	Title
EG24533A (en)	2009-08-30	Piperdine derivatives useful as CCR 5 antagonists
EG24136A (en)	2008-08-06	Piperazine derivatives useful as ccr5 antagonists
EG24433A (en)	2009-06-25	Novel benzolimidazole derivatives useful as antiproliferative agents
EP1206262A4 (de)	2003-01-02	Neuropeptid-y antagonisten: derivate des spiroisoquinolinons
GB9918180D0 (en)	1999-10-06	Novel compositions
GB9921037D0 (en)	1999-11-10	Compositions
PL356990A1 (en)	2004-07-12	Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
IL148623A0 (en)	2002-09-12	Thienoisoxazolyl-and thienylpyrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists
EG22187A (en)	2002-10-31	New composition
AU2673201A (en)	2001-07-03	Alpha-arylethylpiperazine derivatives as neurokinin antagonists
AP2001002273A0 (en)	2001-09-30	Rescorcinol composition
GB9903924D0 (en)	1999-04-14	Cosmectic compositions
GB9929622D0 (en)	2000-02-09	Compositions
GB9904931D0 (en)	1999-04-28	Compositions
GB9926833D0 (en)	2000-01-12	Compositions
GB9914582D0 (en)	1999-08-25	Composition
GB9904614D0 (en)	1999-04-21	Piperidines
IL120313A0 (en)	1997-07-13	Piperidine derivatives as neurokinin antagonists
GB9928217D0 (en)	2000-01-26	New herbicdal compositions
GB9918805D0 (en)	1999-10-13	New heterocyclic pigments
GB9902361D0 (en)	1999-03-24	Ecoflex 2
GB9905572D0 (en)	1999-05-05	Compositions
GB9912423D0 (en)	1999-07-28	Compositions
GB9912421D0 (en)	1999-07-28	Compositions
GB9905571D0 (en)	1999-05-05	Compositions